| Stem definition | Drug id | CAS RN |
|---|---|---|
| antiparasitics, ivermectin derivatives | 3972 | 70288-86-7 |
| Molecule | Description |
|---|---|
|
Synonyms:
|
A mixture of mostly avermectin H2B1a (RN 71827-03-7) with some avermectin H2B1b (RN 70209-81-3), which are macrolides from STREPTOMYCES avermitilis. It binds glutamate-gated chloride channel to cause increased permeability and hyperpolarization of nerve and muscle cells. It also interacts with other CHLORIDE CHANNELS. It is a broad spectrum antiparasitic that is active against microfilariae of ONCHOCERCA VOLVULUS but not the adult form. In vitro data suggest evidence of activity against SARS-CoV-2, but to date available data are insufficient to recommend either for or against the use of ivermectin for the treatment of COVID-19. FDA issued a warning concerning possi-ble inappropriate use of ivermectin products intended for animals as an attempt to self-medicate for the treat-ment of COVID-19.
|
| Dose | Unit | Route |
|---|---|---|
| 12 | mg | O |
| Property | Value | Reference |
|---|---|---|
| BDDCS (Biopharmaceutical Drug Disposition Classification System) | 1 | Benet LZ, Broccatelli F, Oprea TI |
| S (Water solubility) | 4 mg/mL | Benet LZ, Broccatelli F, Oprea TI |
| MRTD (Maximum Recommended Therapeutic Daily Dose) | 0.17 µM/kg/day | Contrera JF, Matthews EJ, Kruhlak NL, Benz RD |
| Date | Agency | Company | Orphan |
|---|---|---|---|
| Nov. 22, 1996 | FDA | MERCK SHARP DOHME |
| MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
|---|---|---|---|---|---|---|
| Conjunctival haemorrhage | 269.98 | 25.18 | 60 | 4329 | 3527 | 63481106 |
| Ocular hyperaemia | 172.60 | 25.18 | 65 | 4324 | 25079 | 63459554 |
| Asthenia | 154.33 | 25.18 | 159 | 4230 | 383445 | 63101188 |
| Headache | 145.82 | 25.18 | 197 | 4192 | 633044 | 62851589 |
| Vertigo | 144.07 | 25.18 | 74 | 4315 | 59813 | 63424820 |
| Malaria | 109.43 | 25.18 | 18 | 4371 | 202 | 63484431 |
| Somatic delusion | 85.57 | 25.18 | 17 | 4372 | 575 | 63484058 |
| Skin irritation | 77.13 | 25.18 | 28 | 4361 | 9713 | 63474920 |
| Coma | 75.65 | 25.18 | 50 | 4339 | 64314 | 63420319 |
| Pyrexia | 68.75 | 25.18 | 119 | 4270 | 470359 | 63014274 |
| Encephalopathy | 60.45 | 25.18 | 36 | 4353 | 38584 | 63446049 |
| Logorrhoea | 56.59 | 25.18 | 16 | 4373 | 2494 | 63482139 |
| Abnormal faeces | 51.91 | 25.18 | 18 | 4371 | 5462 | 63479171 |
| Skin burning sensation | 49.74 | 25.18 | 22 | 4367 | 12712 | 63471921 |
| Depressed level of consciousness | 49.30 | 25.18 | 38 | 4351 | 62040 | 63422593 |
| Gastrointestinal motility disorder | 49.21 | 25.18 | 17 | 4372 | 5102 | 63479531 |
| Product use in unapproved indication | 45.76 | 25.18 | 59 | 4330 | 179021 | 63305612 |
| Urine odour abnormal | 45.53 | 25.18 | 17 | 4372 | 6372 | 63478261 |
| Erythema | 45.05 | 25.18 | 58 | 4331 | 175693 | 63308940 |
| Oral discomfort | 42.84 | 25.18 | 18 | 4371 | 9183 | 63475450 |
| Urinary incontinence | 37.88 | 25.18 | 25 | 4364 | 31989 | 63452644 |
| Pruritus | 34.96 | 25.18 | 77 | 4312 | 361376 | 63123257 |
| Dermatitis contact | 33.52 | 25.18 | 16 | 4373 | 10992 | 63473641 |
| Acute generalised exanthematous pustulosis | 33.39 | 25.18 | 16 | 4373 | 11083 | 63473550 |
| Chromaturia | 32.61 | 25.18 | 18 | 4371 | 16699 | 63467934 |
| Musculoskeletal discomfort | 31.40 | 25.18 | 18 | 4371 | 17949 | 63466684 |
| Rash papular | 30.89 | 25.18 | 17 | 4372 | 15685 | 63468948 |
| Off label use | 29.78 | 25.18 | 108 | 4281 | 674354 | 62810279 |
| Language disorder | 28.05 | 25.18 | 9 | 4380 | 2151 | 63482482 |
| Aphasia | 27.94 | 25.18 | 21 | 4368 | 32979 | 63451654 |
| Vascular purpura | 26.99 | 25.18 | 8 | 4381 | 1470 | 63483163 |
| Abnormal behaviour | 26.00 | 25.18 | 17 | 4372 | 21409 | 63463224 |
| Cheilitis | 25.90 | 25.18 | 10 | 4379 | 4103 | 63480530 |
| Mazzotti reaction | 25.74 | 25.18 | 3 | 4386 | 0 | 63484633 |
| MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
|---|---|---|---|---|---|---|
| Conjunctival haemorrhage | 878.04 | 34.77 | 180 | 5694 | 2875 | 34948182 |
| Ocular hyperaemia | 623.33 | 34.77 | 176 | 5698 | 11276 | 34939781 |
| Asthenia | 483.75 | 34.77 | 366 | 5508 | 244885 | 34706172 |
| Headache | 464.15 | 34.77 | 330 | 5544 | 200305 | 34750752 |
| Coma | 417.33 | 34.77 | 186 | 5688 | 45492 | 34905565 |
| Vertigo | 295.25 | 34.77 | 123 | 5751 | 25413 | 34925644 |
| Pyrexia | 258.04 | 34.77 | 296 | 5578 | 332717 | 34618340 |
| Urinary incontinence | 242.16 | 34.77 | 98 | 5776 | 18776 | 34932281 |
| Malaria | 225.19 | 34.77 | 38 | 5836 | 185 | 34950872 |
| Back pain | 158.74 | 34.77 | 144 | 5730 | 121645 | 34829412 |
| Encephalopathy | 153.10 | 34.77 | 87 | 5787 | 35232 | 34915825 |
| Gait disturbance | 141.97 | 34.77 | 116 | 5758 | 85024 | 34866033 |
| Depressed level of consciousness | 99.05 | 34.77 | 71 | 5803 | 42770 | 34908287 |
| Abnormal behaviour | 88.37 | 34.77 | 54 | 5820 | 24915 | 34926142 |
| Language disorder | 80.15 | 34.77 | 25 | 5849 | 2231 | 34948826 |
| Myalgia | 68.01 | 34.77 | 77 | 5797 | 84033 | 34867024 |
| Nuchal rigidity | 62.70 | 34.77 | 15 | 5859 | 491 | 34950566 |
| Logorrhoea | 62.22 | 34.77 | 21 | 5853 | 2405 | 34948652 |
| Arthralgia | 58.12 | 34.77 | 103 | 5771 | 169938 | 34781119 |
| Rhinocerebral mucormycosis | 55.95 | 34.77 | 14 | 5860 | 554 | 34950503 |
| Filariasis | 53.85 | 34.77 | 7 | 5867 | 0 | 34951057 |
| Anal incontinence | 52.88 | 34.77 | 26 | 5848 | 7823 | 34943234 |
| Adverse event | 52.29 | 34.77 | 35 | 5839 | 18842 | 34932215 |
| Pruritus | 51.07 | 34.77 | 88 | 5786 | 141893 | 34809164 |
| Stupor | 47.53 | 34.77 | 18 | 5856 | 2873 | 34948184 |
| Product use in unapproved indication | 46.45 | 34.77 | 76 | 5798 | 117423 | 34833634 |
| Blood smear test abnormal | 46.15 | 34.77 | 6 | 5868 | 0 | 34951057 |
| Chills | 44.28 | 34.77 | 61 | 5813 | 80982 | 34870075 |
| Strongyloidiasis | 41.42 | 34.77 | 16 | 5858 | 2695 | 34948362 |
| MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
|---|---|---|---|---|---|---|
| Conjunctival haemorrhage | 1124.02 | 25.63 | 234 | 9511 | 5631 | 79729012 |
| Ocular hyperaemia | 742.24 | 25.63 | 230 | 9515 | 27976 | 79706667 |
| Asthenia | 629.12 | 25.63 | 508 | 9237 | 511181 | 79223462 |
| Headache | 491.16 | 25.63 | 492 | 9253 | 653280 | 79081363 |
| Coma | 461.26 | 25.63 | 231 | 9514 | 100418 | 79634225 |
| Vertigo | 405.51 | 25.63 | 188 | 9557 | 68894 | 79665749 |
| Malaria | 335.66 | 25.63 | 56 | 9689 | 366 | 79734277 |
| Pyrexia | 320.76 | 25.63 | 402 | 9343 | 678307 | 79056336 |
| Urinary incontinence | 267.07 | 25.63 | 120 | 9625 | 40789 | 79693854 |
| Encephalopathy | 215.75 | 25.63 | 122 | 9623 | 67275 | 79667368 |
| Depressed level of consciousness | 141.08 | 25.63 | 107 | 9638 | 96545 | 79638098 |
| Back pain | 138.99 | 25.63 | 178 | 9567 | 304002 | 79430641 |
| Gait disturbance | 133.93 | 25.63 | 145 | 9600 | 207361 | 79527282 |
| Abnormal behaviour | 130.32 | 25.63 | 71 | 9674 | 36350 | 79698293 |
| Language disorder | 118.12 | 25.63 | 34 | 9711 | 3180 | 79731463 |
| Logorrhoea | 116.23 | 25.63 | 36 | 9709 | 4329 | 79730314 |
| Somatic delusion | 77.93 | 25.63 | 18 | 9727 | 700 | 79733943 |
| Product use in unapproved indication | 73.64 | 25.63 | 119 | 9626 | 250240 | 79484403 |
| Rhinocerebral mucormycosis | 71.00 | 25.63 | 18 | 9727 | 1040 | 79733603 |
| Strongyloidiasis | 70.58 | 25.63 | 24 | 9721 | 3874 | 79730769 |
| Nuchal rigidity | 70.23 | 25.63 | 18 | 9727 | 1086 | 79733557 |
| Pruritus | 70.12 | 25.63 | 151 | 9594 | 394497 | 79340146 |
| Myalgia | 69.85 | 25.63 | 99 | 9646 | 185542 | 79549101 |
| Anal incontinence | 58.33 | 25.63 | 33 | 9712 | 18135 | 79716508 |
| Filariasis | 56.07 | 25.63 | 7 | 9738 | 0 | 79734643 |
| Agitation | 52.82 | 25.63 | 63 | 9682 | 99652 | 79634991 |
| Stupor | 50.71 | 25.63 | 22 | 9723 | 6850 | 79727793 |
| Chills | 49.56 | 25.63 | 78 | 9667 | 160156 | 79574487 |
| Aphasia | 45.60 | 25.63 | 41 | 9704 | 46691 | 79687952 |
| Eosinophilia | 42.70 | 25.63 | 39 | 9706 | 45306 | 79689337 |
| Adverse event | 40.33 | 25.63 | 43 | 9702 | 60171 | 79674472 |
| Speech disorder | 38.46 | 25.63 | 40 | 9705 | 54405 | 79680238 |
| Blood smear test abnormal | 37.15 | 25.63 | 6 | 9739 | 31 | 79734612 |
| Gastrointestinal motility disorder | 36.86 | 25.63 | 17 | 9728 | 6105 | 79728538 |
| Dysstasia | 36.67 | 25.63 | 29 | 9716 | 27717 | 79706926 |
| Urine odour abnormal | 36.46 | 25.63 | 17 | 9728 | 6256 | 79728387 |
| Decubitus ulcer | 36.09 | 25.63 | 23 | 9722 | 15664 | 79718979 |
| Loss of consciousness | 35.31 | 25.63 | 69 | 9676 | 167874 | 79566769 |
| Abnormal faeces | 33.43 | 25.63 | 17 | 9728 | 7554 | 79727089 |
| Off label use | 32.97 | 25.63 | 206 | 9539 | 907009 | 78827634 |
| Skin irritation | 32.30 | 25.63 | 19 | 9726 | 11221 | 79723422 |
| Oral discomfort | 32.06 | 25.63 | 18 | 9727 | 9742 | 79724901 |
| Mazzotti reaction | 32.04 | 25.63 | 4 | 9741 | 0 | 79734643 |
| Diarrhoea | 32.03 | 25.63 | 200 | 9545 | 880289 | 78854354 |
| Skin burning sensation | 31.88 | 25.63 | 20 | 9725 | 13252 | 79721391 |
| Fall | 31.87 | 25.63 | 10 | 9735 | 487619 | 79247024 |
| Disseminated strongyloidiasis | 30.88 | 25.63 | 7 | 9738 | 250 | 79734393 |
| Fatigue | 30.09 | 25.63 | 42 | 9703 | 929685 | 78804958 |
| Disorientation | 27.37 | 25.63 | 36 | 9709 | 62740 | 79671903 |
| Eyelid oedema | 26.45 | 25.63 | 18 | 9727 | 13669 | 79720974 |
| Paresis | 26.18 | 25.63 | 12 | 9733 | 4249 | 79730394 |
| Conjunctival hyperaemia | 25.78 | 25.63 | 12 | 9733 | 4401 | 79730242 |
None
| Source | Code | Description |
|---|---|---|
| ATC | D11AX22 | DERMATOLOGICALS OTHER DERMATOLOGICAL PREPARATIONS OTHER DERMATOLOGICAL PREPARATIONS Other dermatologicals |
| ATC | P02CF01 | ANTIPARASITIC PRODUCTS, INSECTICIDES AND REPELLENTS ANTHELMINTICS ANTINEMATODAL AGENTS Avermectines |
| FDA EPC | N0000175484 | Antiparasitic |
| MeSH PA | D000890 | Anti-Infective Agents |
| MeSH PA | D000977 | Antiparasitic Agents |
| MeSH PA | D007306 | Insecticides |
| MeSH PA | D010575 | Pesticides |
| CHEBI has role | CHEBI:24852 | insecticides |
| CHEBI has role | CHEBI:35443 | anthelmintics |
| CHEBI has role | CHEBI:35444 | antinematodal drugs |
| CHEBI has role | CHEBI:35820 | antiprotozoal drugs |
| CHEBI has role | CHEBI:73333 | scabicides |
| FDA EPC | N0000181811 | Pediculicide |
| Disease | Relation | SNOMED_ID | DOID |
|---|---|---|---|
| Infection by Strongyloides | indication | 1214006 | DOID:10955 |
| Infection by Onchocerca volvulus | indication | 38539003 | DOID:11678 |
| Infection by Loa loa | contraindication | 44250009 | DOID:13523 |
| Liver function tests abnormal | contraindication | 166603001 |
| Species | Use | Relation |
|---|---|---|
| Bison | Treatment and control of grubs, Hypoderma bovis | Indication |
| Cats | Prevents heartworm disease | Indication |
| Cats | Removal and control of adult and immature (L4) hookworms, Ancylostoma tubaeforme | Indication |
| Cats | Removal and control of adult and immature (L4) hookworms, A braziliense | Indication |
| Cats | Treatment of adult ear mite (Otodectes cynotis) | Indication |
| Cattle | Treatment and control of gastrointestinal nematodes, Haemonchus placei (adults and fourth-stage larvae) | Indication |
| Cattle | Treatment and control of gastrointestinal nematodes, Ostertagia ostertagi (adults and fourth-stage larvae) | Indication |
| Cattle | Treatment and control of gastrointestinal nematodes, O lyrata (adults and fourth-stage larvae) | Indication |
| Cattle | Treatment and control of gastrointestinal nematodes, Trichostrongylus axei (adults and fourth-stage larvae) | Indication |
| Cattle | Treatment and control of gastrointestinal nematodes, T colubriformis (adults and fourth-stage larvae) | Indication |
| Cattle | Treatment and control of gastrointestinal nematodes, Cooperia oncophora (adults and fourth-stage larvae) | Indication |
| Cattle | Treatment and control of gastrointestinal nematodes, C punctata (adults and fourth-stage larvae) | Indication |
| Cattle | Treatment and control of gastrointestinal nematodes, C pectinata (adults and fourth-stage larvae) | Indication |
| Cattle | Treatment and control of gastrointestinal nematodes, Oesophagostomum radiatum (adults and fourth-stage larvae) | Indication |
| Cattle | Treatment and control of gastrointestinal nematodes, Nematodirus helvetianus (adults) | Indication |
| Cattle | Treatment and control of gastrointestinal nematodes, N spathiger (adults) | Indication |
| Cattle | Treatment and control of gastrointestinal nematodes, Bunostomum phlebotomum (adults and fourth-stage larvae) | Indication |
| Cattle | Treatment and control of lungworms, Dictyocaulus viviparus, (adult and L4) | Indication |
| Cattle | Treatment and control of grubs, Hypoderma bovis | Indication |
| Cattle | Treatment and control of grubs, H lineatum | Indication |
| Cattle | Treatment and control of sucking lice, Linognathus vituli | Indication |
| Cattle | Treatment and control of sucking lice Haematopinus eurysternus | Indication |
| Cattle | Treatment and control of sucking lice, Solenopotes capillatus | Indication |
| Cattle | Treatment and control of mites, Psoroptes ovis | Indication |
| Cattle | Treatment and control of mites, Sarcoptes scabiei var bovis | Indication |
| Cattle | Protection (28 days) from reinfection with D viviparus | Indication |
| Cattle | Protection (28 days) from reinfection with O radiatum | Indication |
| Cattle | Protection (21 days) from reinfection with O ostertagi | Indication |
| Cattle | Protection (21 days) from reinfection with T axei | Indication |
| Cattle | Protection (21 days) from reinfection with C punctata | Indication |
| Cattle | Protection (14 days) from reinfection with H placei | Indication |
| Cattle | Protection (14 days) from reinfection with C oncophora | Indication |
| Cervidae | Treatment and control of warbles, Oedemagena tarandi | Indication |
| Dogs | Prevention of heartworm disease | Indication |
| Foxes | Ear mite (Otodectes cynotis) infestations | Indication |
| Horses | Treatment and control of large strongyles, Strongylus vulgaris (adults) | Indication |
| Horses | Treatment and control of large strongyles, S edentatus (adults) | Indication |
| Horses | Treatment and control of large strongyles, S equinus | Indication |
| Horses | Treatment and control of large strongyles, Triodontophorus spp (adults) | Indication |
| Horses | Treatment and control of large strongyles, Craterostomum acuticaudatum (adults) | Indication |
| Horses | Treatment and control of small strongyles, Coronocyclus spp (adults) | Indication |
| Horses | Treatment and control of small strongyles, Cyathostomum spp (adults) | Indication |
| Horses | Treatment and control of small strongyles, Cylicocyclus spp (adults) | Indication |
| Horses | Treatment and control of small strongyles, Cylicodontophorus spp (adults) | Indication |
| Horses | Treatment and control of small strongyles, Cylicostephanus spp (adults) | Indication |
| Horses | Treatment and control of small strongyles, Petrovinema poculatum (adults) | Indication |
| Horses | Indication | |
| Horses | Treatment and control of small strongyles, (fourth-stage larvae) | Indication |
| Horses | Treatment and control of pinworms Oxyuris equi (adults and fourth stage larvae) | Indication |
| Horses | Treatment and control of ascarids (adults and third- and fourth-stage larvae) Parascaris equorum | Indication |
| Horses | Treatment and control of Hairworms, Trichostrongylus axei (adults) | Indication |
| Horses | Treatment and control of Large mouth Stomach Worms, Habronema muscae (adults) | Indication |
| Horses | Treatment and control of bots, (oral and gastric stages) Gasterophilus spp | Indication |
| Horses | Treatment and control of Lungworms, Dictyocaulus arnfieldi (adults and fourth-stage larvae) | Indication |
| Horses | Treatment and control of Intestinal Threadworms, Strongyloides westeri (adults) | Indication |
| Horses | Summer sores caused by Habronema | Indication |
| Horses | Summer sores caused by Draschia spp cutaneous third-stage larvae | Indication |
| Horses | Dermatitis caused by neck threadworm microfilariae, Onchocerca sp | Indication |
| Sheep | Treatment and control of the adult and fourth-stage larvae of gastrointestinal roundworms, Haemonchus contortus | Indication |
| Sheep | Treatment and control of the adult and fourth-stage larvae of gastrointestinal roundworms, H placei (adults only) | Indication |
| Sheep | Treatment and control of the adult and fourth-stage larvae of gastrointestinal roundworms, Ostertagia circumcincta | Indication |
| Sheep | Treatment and control of the adult and fourth-stage larvae of gastrointestinal roundworms, Trichostrongylus axei | Indication |
| Sheep | Treatment and control of the adult and fourth-stage larvae of gastrointestinal roundworms, T colubriformis | Indication |
| Sheep | Treatment and control of the adult and fourth-stage larvae of gastrointestinal roundworms, Cooperia oncophora (adults only) | Indication |
| Sheep | Treatment and control of the adult and fourth-stage larvae of gastrointestinal roundworms, C curticei | Indication |
| Sheep | Treatment and control of the adult and fourth-stage larvae of gastrointestinal roundworms, Oesophagostomum columbianum | Indication |
| Sheep | Treatment and control of the adult and fourth-stage larvae of gastrointestinal roundworms, O venulosum (adults only) | Indication |
| Sheep | Treatment and control of the adult and fourth-stage larvae of gastrointestinal roundworms, Nematodirus battus | Indication |
| Sheep | Treatment and control of the adult and fourth-stage larvae of gastrointestinal roundworms, N spathiger | Indication |
| Sheep | Treatment and control of the adult and fourth-stage larvae of gastrointestinal roundworms, S papillosus (adults only) | Indication |
| Sheep | Treatment and control of the adult and fourth-stage larvae of gastrointestinal roundworms, Chabertia ovina (adult only) | Indication |
| Sheep | Treatment and control of the gastrointestinal roundworms, Trichuris ovis (adults only) | Indication |
| Sheep | Treatment and control of the nasal bot, Oestrus ovis | Indication |
| Sheep | Treatment and control of lungworms, D filaria | Indication |
| Swine | Treatment and control of gastrointestinal roundworms, Ascaris suum (adults and fourth-stage larvae) | Indication |
| Swine | Treatment and control of gastrointestinal roundworms, Ascarops strongylina (adults) | Indication |
| Swine | Treatment and control of gastrointestinal roundworms, Hyostrongylus rubidus (adults and fourth-stage larvae) | Indication |
| Swine | Treatment and control of gastrointestinal roundworms, Oesophagostomum species (adults and fourth-stage larvae) | Indication |
| Swine | Treatment and control of kidneyworms, Stephanurus dentatus (adults and fourth-stage larvae) | Indication |
| Swine | Treatment and control of lungworms, Metastrongylus species (adults) | Indication |
| Swine | Treatment and control of lice, Haematopinus suis | Indication |
| Swine | Treatment and control of mange mites, Sarcoptes scabiei var suis | Indication |
| Product | Applicant | Ingredients |
|---|---|---|
| Eqvalan Injection | Boehringer lngelheim Animal Health USA Inc. | 1 |
| Ivomec .27% Injection Grower And Feeder Pigs, Ivomec 1% Injection, Ivomec 1% Injection for Cattle And Swine, Ivomec Injection for Cattle | Boehringer lngelheim Animal Health USA Inc. | 1 |
| Ivomec Liquid | Boehringer lngelheim Animal Health USA Inc. | 1 |
| EQVALAN | Boehringer lngelheim Animal Health USA Inc. | 1 |
| Ivomec Cattle Paste 0.153% | Boehringer lngelheim Animal Health USA Inc. | 1 |
| Heartgard 30, Heartgard Tablets | Boehringer lngelheim Animal Health USA Inc. | 1 |
| Eqvalan Oral Liquid For Horses | Boehringer lngelheim Animal Health USA Inc. | 1 |
| Ivomec Plus Injection For Cattle | Boehringer lngelheim Animal Health USA Inc. | 2 |
| Ivomec Pour-On | Boehringer lngelheim Animal Health USA Inc. | 1 |
| Heartgard Chewables For Dogs | Boehringer lngelheim Animal Health USA Inc. | 1 |
| Heartgard Plus | Boehringer lngelheim Animal Health USA Inc. | 2 |
| Ivomec Premix for Swine | Boehringer lngelheim Animal Health USA Inc. | 1 |
| Ivomec Sustained-Release Bolus for Cattle | Boehringer lngelheim Animal Health USA Inc. | 1 |
| Heartgard for Cats | Boehringer lngelheim Animal Health USA Inc. | 1 |
| BMD / Ivomec Premix for Swine | Boehringer lngelheim Animal Health USA Inc. | 2 |
| Acarexx | Boehringer lngelheim Animal Health USA Inc. | 1 |
| Advantage DUO | Elanco US Inc. | 2 |
| ZIMECTERIN Gold Paste | Boehringer lngelheim Animal Health USA Inc. | 2 |
| Equimax | Virbac AH Inc. | 2 |
| Zimecterin-EZ | Farnam Companies Inc. | 1 |
| Iverhart Max | Virbac AH Inc. | 3 |
| Panacur Plus | Intervet Inc. | 3 |
| Duocare | Boehringer lngelheim Animal Health USA Inc. | 2 |
| IVERHART MAX Chew | Virbac AH Inc. | 3 |
| Phoenectin | Elanco US Inc. | 1 |
| Ivermectin Pour-On for Cattle, Phoenectin, Phoenectin, Phoenectin Pour-On for Cattle | Huvepharma EOOD | 1 |
| Phoenectin | Huvepharma EOOD | 1 |
| Iverhart Tablets | Virbac AH Inc. | 1 |
| Noromectin Pour-On for Cattle | Norbrook Laboratories, Ltd. | 1 |
| Phoenectin Paste 1.87% | Elanco US Inc. | 1 |
| Iversol Liquid for Horses | Med-Pharmex Inc. | 1 |
| Ivermectin Chewable Tablets | Cronus Pharma Specialities India Private Limited | 1 |
| Iver-On | Med-Pharmex Inc. | 1 |
| Iverhart Plus Flavored Chewables | Virbac AH Inc. | 2 |
| Bimectin Pour-On | Bimeda Animal Health Limited | 1 |
| Equell | Virbac AH Inc. | 1 |
| Primectin Equine Oral Liquid | First Priority Inc. | 1 |
| Bimectin | Bimeda Animal Health Limited | 1 |
| Privermectin Drench for Sheep | First Priority Inc. | 1 |
| Tri-Heart Plus Chewable Tablets | Heska Corp. | 2 |
| Privermectin | First Priority Inc. | 1 |
| SparMectin-E | Sparhawk Laboratories Inc. | 1 |
| Ecomectin | Huvepharma EOOD | 1 |
| Ivermectin Paste 1.87 % | Med-Pharmex Inc. | 1 |
| Ivermectin Injection | Sparhawk Laboratories Inc. | 1 |
| Normectin Plus | Norbrook Laboratories, Ltd. | 2 |
| Noromectin | Norbrook Laboratories, Ltd. | 1 |
| Bimectin Injection for Cattle and Swine | Bimeda Animal Health Limited | 1 |
| Bimectin Plus | Bimeda Animal Health Limited | 2 |
| SparMectin Plus Clorsulon | Sparhawk Laboratories Inc. | 2 |
| Animec Plus | Chanelle Pharmaceuticals Manufacturing Ltd. | 1 |
| Ivermectin Paste 1.87% | Boehringer lngelheim Animal Health USA Inc. | 1 |
None
| Formulation strength | Trade name | Applicant | Application number | Approval date | Type | Dose form | Route | Patent number | Patent expiration date | Patent use |
|---|---|---|---|---|---|---|---|---|---|---|
| 1% | SOOLANTRA | GALDERMA LABS LP | N206255 | Dec. 19, 2014 | RX | CREAM | TOPICAL | 7550440 | April 22, 2024 | TREATMENT OF INFLAMMATORY LESIONS OF ROSACEA. |
| 1% | SOOLANTRA | GALDERMA LABS LP | N206255 | Dec. 19, 2014 | RX | CREAM | TOPICAL | 8080530 | April 22, 2024 | TREATMENT OF INFLAMMATORY LESIONS OF ROSACEA. |
| 1% | SOOLANTRA | GALDERMA LABS LP | N206255 | Dec. 19, 2014 | RX | CREAM | TOPICAL | 8093219 | April 22, 2024 | TREATMENT OF INFLAMMATORY LESIONS OF ROSACEA. |
| 1% | SOOLANTRA | GALDERMA LABS LP | N206255 | Dec. 19, 2014 | RX | CREAM | TOPICAL | 8415311 | April 22, 2024 | TREATMENT OF INFLAMMATORY LESIONS OF ROSACEA. |
| 1% | SOOLANTRA | GALDERMA LABS LP | N206255 | Dec. 19, 2014 | RX | CREAM | TOPICAL | 8470788 | April 22, 2024 | TREATMENT OF INFLAMMATORY LESIONS OF ROSACEA. |
| 1% | SOOLANTRA | GALDERMA LABS LP | N206255 | Dec. 19, 2014 | RX | CREAM | TOPICAL | 8815816 | April 22, 2024 | TREATMENT OF INFLAMMATORY LESIONS OF ROSACEA. |
| 1% | SOOLANTRA | GALDERMA LABS LP | N206255 | Dec. 19, 2014 | RX | CREAM | TOPICAL | 10206939 | March 13, 2034 | TREATMENT OF INFLAMMATORY LESIONS OF ROSACEA. |
| 1% | SOOLANTRA | GALDERMA LABS LP | N206255 | Dec. 19, 2014 | RX | CREAM | TOPICAL | 9089587 | March 13, 2034 | TREATMENT OF INFLAMMATORY LESIONS OF ROSACEA. |
| 1% | SOOLANTRA | GALDERMA LABS LP | N206255 | Dec. 19, 2014 | RX | CREAM | TOPICAL | 9233117 | March 13, 2034 | TREATMENT OF INFLAMMATORY LESIONS OF ROSACEA. |
| 1% | SOOLANTRA | GALDERMA LABS LP | N206255 | Dec. 19, 2014 | RX | CREAM | TOPICAL | 9233118 | March 13, 2034 | TREATMENT OF INFLAMMATORY LESIONS OF ROSACEA. |
| 1% | SOOLANTRA | GALDERMA LABS LP | N206255 | Dec. 19, 2014 | RX | CREAM | TOPICAL | 9782425 | March 13, 2034 | TREATMENT OF INFLAMMATORY LESIONS OF ROSACEA. |
None
| Target | Class | Pharos | UniProt | Action | Type | Activity value (-log[M]) | Mechanism action | Bioact source | MoA source |
|---|---|---|---|---|---|---|---|---|---|
| Multidrug resistance protein 1 | Transporter | IC50 | 7 | WOMBAT-PK | |||||
| Sodium-dependent noradrenaline transporter | Transporter | Ki | 5.41 | DRUG MATRIX | |||||
| D(3) dopamine receptor | GPCR | Ki | 6.13 | DRUG MATRIX | |||||
| Muscarinic acetylcholine receptor M1 | GPCR | Ki | 5.92 | DRUG MATRIX | |||||
| Muscarinic acetylcholine receptor M3 | GPCR | Ki | 5.89 | DRUG MATRIX | |||||
| Muscarinic acetylcholine receptor M5 | GPCR | Ki | 5.59 | DRUG MATRIX | |||||
| Alpha-2C adrenergic receptor | GPCR | Ki | 6.24 | DRUG MATRIX | |||||
| Sodium-dependent dopamine transporter | Transporter | Ki | 5.45 | DRUG MATRIX | |||||
| Adenosine receptor A3 | GPCR | Ki | 6.54 | DRUG MATRIX | |||||
| Neuronal acetylcholine receptor subunit alpha-7 | Ion channel | ALLOSTERIC MODULATOR | EC50 | 5.10 | IUPHAR | ||||
| Bile acid receptor | Nuclear hormone receptor | IC50 | 6.59 | CHEMBL | |||||
| Glycine Receptor | Ion channel | AGONIST | EC50 | 6.40 | IUPHAR | ||||
| D(1A) dopamine receptor | GPCR | Ki | 5.65 | DRUG MATRIX | |||||
| Alpha-2A adrenergic receptor | GPCR | Ki | 5.66 | DRUG MATRIX | |||||
| Glutamate-gated chloride channel | Ion channel | MODULATOR | CHEMBL | CHEMBL | |||||
| Glutamate-gated chloride channel | Ion channel | MODULATOR | CHEMBL | CHEMBL | |||||
| Sarcoplasmic/endoplasmic reticulum calcium ATPase 2 | Enzyme | IC50 | 5.17 | CHEMBL | |||||
| Sodium/potassium-transporting ATPase subunit alpha-1 | Enzyme | IC50 | 5.08 | CHEMBL | |||||
| Sarcoplasmic/endoplasmic reticulum calcium ATPase 1 | Enzyme | IC50 | 4.77 | CHEMBL | |||||
| P2X purinoceptor 4 | Ion channel | ALLOSTERIC MODULATOR | EC50 | 6.60 | IUPHAR |
| ID | Source |
|---|---|
| 4021046 | VUID |
| N0000148510 | NUI |
| D00804 | KEGG_DRUG |
| 4021046 | VANDF |
| C0022322 | UMLSCUI |
| CHEBI:6078 | CHEBI |
| IVM | PDB_CHEM_ID |
| CHEMBL1200633 | ChEMBL_ID |
| D007559 | MESH_DESCRIPTOR_UI |
| DB00602 | DRUGBANK_ID |
| 2373 | IUPHAR_LIGAND_ID |
| 4828 | INN_ID |
| 8883YP2R6D | UNII |
| 6321424 | PUBCHEM_CID |
| 6069 | RXNORM |
| 4941 | MMSL |
| 71965 | MMSL |
| d04101 | MMSL |
| 005266 | NDDF |
| 387559003 | SNOMEDCT_US |
| 96138006 | SNOMEDCT_US |
| Product | Category | Ingredients | NDC | Form | Quantity | Route | Marketing | Label |
|---|---|---|---|---|---|---|---|---|
| STROMECTOL | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0006-0032 | TABLET | 3 mg | ORAL | NDA | 26 sections |
| STROMECTOL | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0006-0032 | TABLET | 3 mg | ORAL | NDA | 26 sections |
| SOOLANTRA | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0299-3823 | CREAM | 10 mg | TOPICAL | NDA | 27 sections |
| SOOLANTRA | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0299-3823 | CREAM | 10 mg | TOPICAL | NDA | 27 sections |
| Ivermectin | HUMAN OTC DRUG LABEL | 1 | 0363-4230 | LOTION | 5 mg | TOPICAL | ANDA | 16 sections |
| Ivermectin | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0574-2107 | CREAM | 10 mg | TOPICAL | NDA authorized generic | 27 sections |
| Ivermectin | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0574-2107 | CREAM | 10 mg | TOPICAL | NDA authorized generic | 27 sections |
| Ivermectin | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0574-2107 | CREAM | 10 mg | TOPICAL | NDA authorized generic | 27 sections |
| Ivermectin | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0591-4052 | CREAM | 10 mg | TOPICAL | ANDA | 26 sections |
| Ivermectin | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0591-4052 | CREAM | 10 mg | TOPICAL | ANDA | 26 sections |
| Ivermectin | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0591-4052 | CREAM | 10 mg | TOPICAL | ANDA | 26 sections |
| Ivermectin | HUMAN OTC DRUG LABEL | 1 | 11822-4230 | LOTION | 5 mg | TOPICAL | ANDA | 16 sections |
| Sklice | HUMAN OTC DRUG LABEL | 1 | 24338-185 | LOTION | 5 mg | TOPICAL | NDA | 16 sections |
| Sklice | HUMAN OTC DRUG LABEL | 1 | 24338-185 | LOTION | 5 mg | TOPICAL | NDA | 16 sections |
| Ivermectin | Human Prescription Drug Label | 1 | 42799-806 | TABLET | 3 mg | ORAL | ANDA | 25 sections |
| Ivermectin | Human Prescription Drug Label | 1 | 42799-806 | TABLET | 3 mg | ORAL | ANDA | 25 sections |
| Ivermectin | HUMAN PRESCRIPTION DRUG LABEL | 1 | 50090-5587 | TABLET | 3 mg | ORAL | ANDA | 24 sections |
| Ivermectin | HUMAN PRESCRIPTION DRUG LABEL | 1 | 50090-5587 | TABLET | 3 mg | ORAL | ANDA | 24 sections |
| Ivermectin | HUMAN OTC DRUG LABEL | 1 | 51316-423 | LOTION | 5 mg | TOPICAL | ANDA | 16 sections |
| Ivermectin | HUMAN PRESCRIPTION DRUG LABEL | 1 | 51672-4211 | LOTION | 5 mg | TOPICAL | ANDA | 27 sections |
| Ivermectin | HUMAN OTC DRUG LABEL | 1 | 51672-4230 | LOTION | 5 mg | TOPICAL | ANDA | 17 sections |
| Ivermectin | HUMAN OTC DRUG LABEL | 1 | 51672-4230 | LOTION | 5 mg | TOPICAL | ANDA | 17 sections |
| STROMECTOL | HUMAN PRESCRIPTION DRUG LABEL | 1 | 55695-019 | TABLET | 3 mg | ORAL | NDA | 26 sections |
| Ivermectin | HUMAN PRESCRIPTION DRUG LABEL | 1 | 63629-8754 | CREAM | 10 mg | TOPICAL | ANDA | 25 sections |
| Ivermectin | HUMAN PRESCRIPTION DRUG LABEL | 1 | 63629-8754 | CREAM | 10 mg | TOPICAL | ANDA | 25 sections |
| Ivermectin | HUMAN PRESCRIPTION DRUG LABEL | 1 | 63629-8754 | CREAM | 10 mg | TOPICAL | ANDA | 25 sections |
| Ivermectin | HUMAN PRESCRIPTION DRUG LABEL | 1 | 66993-948 | CREAM | 10 mg | TOPICAL | NDA authorized generic | 26 sections |
| Ivermectin | HUMAN PRESCRIPTION DRUG LABEL | 1 | 68071-2242 | TABLET | 3 mg | ORAL | ANDA | 25 sections |
| ivermectin | HUMAN PRESCRIPTION DRUG LABEL | 1 | 70771-1728 | CREAM | 10 mg | TOPICAL | ANDA | 2 sections |
| ivermectin | HUMAN PRESCRIPTION DRUG LABEL | 1 | 72578-120 | CREAM | 10 mg | TOPICAL | ANDA | 24 sections |